Global COVID-19 cases surpass 75 million

Reuters 12/21/2020

Global coronavirus infections surpassed the 75 million mark on Saturday, according to a Reuters tally, as several nations around the world begin vaccinating against the virus. Britain this month became the first Western country to start immunizing…

Teachers should receive vaccine priority — UNICEF

AFP Relaxnews 12/17/2020

The head of the U.N. children’s agency, UNICEF, called Tuesday for teachers to be among those given priority access to the COVID-19 vaccines. “The COVID-19 pandemic has wreaked havoc on children’s education around the globe. Vaccinating teachers…

Cebu City tagged as priority for COVID-19 vaccines

Delta Dyrecka Letigio 12/15/2020

CEBU CITY, Philippines — Cebu City will have ample allocation of the Coronavirus Disease 2019 (COVID-19) vaccine should the national government be able to purchase it from an accredited source. This was revealed by Mayor Edgardo Labella…

Trump says first US vaccine will be administered ‘in less than 24 hours’

Inquirer 12/12/2020

WASHINGTON – President Donald Trump said the US will start administering the Pfizer-BioNTech Covid-19 vaccine “in less than 24 hours,” after the Food and Drug Administration granted it an emergency use authorization late Friday. “The first vaccine…

Britain’s Queen Elizabeth to get COVID-19 vaccine ‘in weeks’: reports

Agence France Presse 12/06/2020

LONDON, United Kingdom  – Britain’s Queen Elizabeth II will receive the Pfizer-BioNTech coronavirus vaccine within weeks, after UK regulators granted emergency approval and the world’s first roll-out begins next week, reports late Saturday said. The monarch, 94,…

Oxford COVID-19 vaccine safe for older adults—results

Agence France Presse 11/21/2020

A leading COVID-19 vaccine candidate has shown to safely produce a robust immune response in healthy older adults, its British makers said Thursday as it released its phase 2 trial results. The vaccine, developed by the University…

COVID-19 vaccine may be ready by year-end—WHO

Reuters 10/07/2020

GENEVA— A vaccine against COVID-19 may be ready by year-end, the head of the World Health Organization (WHO) said on Tuesday, without elaborating. WHO Director-General Tedros Adhanom Ghebreyesus, addressing the end of a two-day meeting of its…

Late-stage study of first single-shot vaccine begins in US

09/23/2020

Johnson & Johnson is beginning a huge final study to try to prove if a single-dose COVID-19 vaccine can protect against the virus. The study starting Wednesday will be one of the world’s largest coronavirus vaccine studies…

13 hospitals to participate in COVID-19 vaccine solidarity trials — DOST

Consuelo Marquez 09/22/2020

MANILA, Philippines — Thirteen hospitals will be involved in the solidarity trials for a potential COVID-19 vaccine in the country which will be conducted this year, the Department of Science and Technology (DOST) said Tuesday. “In his…

Labella welcomes Cebu as area for COVID vaccine trial

Morexette Marie B. Erram 09/11/2020

CEBU CITY, Philippines — Cebu City Mayor Edgardo Labella welcomed the announcement from the national government that they would be conducting clinical trials for the coronavirus vaccine here in Cebu. “Nalipay ko ug dawaton nato na kay…

PH to go for less expensive COVID-19 vaccine once available

Krissy Aguilar 09/08/2020

MANILA, Philippines — The Philippines would opt to buy a less expensive vaccine for COVID-19 regardless of which country it came from, President Rodrigo Duterte said Monday. “As I said, it’s there. I think it’s Moderna. It’s…

AstraZeneca’s COVID-19 vaccine candidate enters late-stage study in US

Reuters 09/01/2020

AstraZeneca Plc said on Monday it began to enroll 30,000 participants aged above 18 in a late-stage study to evaluate its COVID-19 vaccine candidate, AZD1222. Participants are being randomized to receive two doses of either AZD1222 or…

Previous           Next
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.